HEMANGEOL Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Hemangeol, and what generic alternatives are available?

Hemangeol is a drug marketed by Pierre Fabre and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has forty-seven patent family members in thirty-one countries.

The generic ingredient in HEMANGEOL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Hemangeol

A generic version of HEMANGEOL was approved as propranolol hydrochloride by INNOGENIX on October 22^nd, 1985.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for HEMANGEOL?
What are the global sales for HEMANGEOL?
What is Average Wholesale Price for HEMANGEOL?

Summary for HEMANGEOL

International Patents:	47
US Patents:	2
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	156
Clinical Trials:	4
Patent Applications:	3,873
Drug Prices:	Drug price information for HEMANGEOL
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for HEMANGEOL
What excipients (inactive ingredients) are in HEMANGEOL?	HEMANGEOL excipients list
DailyMed Link:	HEMANGEOL at DailyMed

Drug patent expirations by year for HEMANGEOL

Recent Clinical Trials for HEMANGEOL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Christiana Care Health Services	Phase 1
Columbia University	Phase 2
University of Missouri-Columbia	Early Phase 1

See all HEMANGEOL clinical trials

Pharmacology for HEMANGEOL

Drug Class	beta-Adrenergic Blocker
Mechanism of Action	Adrenergic beta-Antagonists

Paragraph IV (Patent) Challenges for HEMANGEOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
HEMANGEOL	Oral Solution	propranolol hydrochloride	4.28 mg/mL	205410	1	2022-07-21

US Patents and Regulatory Information for HEMANGEOL

HEMANGEOL is protected by two US patents.

Patents protecting HEMANGEOL

Use of a beta blocker for the manufacture of a medicament for the treatment of hemangiomas
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD TO TREAT HEMANGIOMA.

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pierre Fabre	HEMANGEOL	propranolol hydrochloride	SOLUTION;ORAL	205410-001	Mar 14, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Pierre Fabre	HEMANGEOL	propranolol hydrochloride	SOLUTION;ORAL	205410-001	Mar 14, 2014		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

International Patents for HEMANGEOL

See the table below for patents covering HEMANGEOL around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
South Korea	101562627		⤷ Sign Up
Cyprus	1112604		⤷ Sign Up
Panama	8799401	USO DE UN BETA BLOQUEANTE PARA LA FABRICACION DE UN MEDICAMENTO PARA EL TRATAMIENTO DE LOS HEMANGIOMAS	⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration